Biogen (BIIB)
(Real Time Quote from BATS)
$201.08 USD
+1.30 (0.65%)
Updated Aug 8, 2024 09:50 AM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 601 - 620 ( 818 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Our Takeaways From the Discontinuation of Aducanumab; Reit Buy and Lowering PT to $300
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
A Good, if Small Step Toward Diversification, But We Like Both the Assets and Indications; Reit Buy and $363 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Deep Dive Into the Institution of Mylan?s IPR for Tecfidera?s ?514 Patent
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Believe the Multi-franchise Vision Should Take Shape in the Coming Years; Reit Buy and $363 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
An Update From 2018 CTAD: the Ever-expanding World of Alzheimer?s Disease (AD) Down the Rabbit Hole
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts Following the Updated BAN2401 Data at the CTAD 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
We See Strength in the Fundamental Business and Ample Upside From the Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A